Ask AI
ProCE Banner Activity

Immunologic Benefit Despite Delayed Virologic Suppression in Multidrug-Resistant HIV: What Is the Significance?

Clinical Thought

This case discussion highlights the management of multidrug-resistant HIV in the setting of comorbidities and explores the potential immunologic benefit of antiretroviral therapy even in the context of delayed virologic suppression.

Released: January 06, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from ViiV Healthcare.

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, and other healthcare professionals involved in the care of people living with HIV.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Devise antiretroviral treatment strategies for people with multidrug-resistant HIV that leverage the attributes of agents approved for use in this setting

Disclosure

Primary Author

Judith A. Aberg, MD: consultant/advisor/speaker: Invivyd, Merck, ViiV; researcher (paid to institution): Gilead; researcher: GSK, Janssen, MacroGenics, Merck, Pfizer, ViiV; other financial or material support: ViiV.